Alimera Sciences has begun enrolling patients in a pilot study to assess the safety and efficacy of its Iluvien insert in patients with macular edema due to retinal vein occlusion, the company announced in a press release. The randomized, double-masked FAVOR (Fluocinolone acetonide for vein occlusion in retina) trial will compare 0.23 µg...

The ANCHOR trial 2-year results report that the incidence of serious nonocular hemorrhage is only slightly higher in the Lucentis (ranibizumab) group, and that the temporal pattern of these events in relation to Lucentis dosing did not suggest a causal association. VEGF plays an important role in the healing of mucosal ulcers in the...

Regeneron Pharmaceuticals announced that the first patient has been enrolled in the Phase 3 program of VEGF Trap-Eye for the treatment of central retinal vein occlusion (CRVO), a leading cause of blindness in adults. Regeneron also announced that enrollment in the Phase 2 DA VINCI study of VEGF Trap-Eye in diabetic macular edema (DME) has been...

Based on 6-month results from a phase 3 safety and efficacy study, Lucentis (ranibizumab) injection improved vision among patients with macular edema due to central retinal vein occlusion, Genentech announced in a press release. The randomized, double-masked, sham-controlled, 12-month CRUISE trial, which enrolled 392 patients with macular edema...

Results of the dry AMD treatment with Rheopheresis trial (ART) find that Rheopheresis is a safe and effective therapeutic option for patients with dry AMD. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders. The dry AMD treatment with Rheopheresis...

ThromboGenics announces that microplasmin, which is in Phase III trials for the treatment of vitreomacular adhesion, is progressing according to schedule. Microplasmin's Phase III program is referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program. This program involves two...

OXiGENE has initiated a phase 2 study of its vascular-disrupting agent ZYBRESTAT (fosbretabulin) for treating patients with polypoidal choroidal vasculopathy (PCV), the company announced in a press release. PCV is a form of choroidal neovascularization characterized by the growth of abnormal blood vessels in the choroid and is similar to wet...

In a phase 3 study, Lucentis (ranibizumab) injection improved vision in patients with macular edema due to branch retinal vein occlusion (BRVO), Genentech announced in a press release. The BRAVO trial, a multicenter, randomized, double-masked, sham injection-controlled phase 3 study, is designed to assess the safety and efficacy of Lucentis in...

A new study of patients with neovascular age-related macular degeneration (AMD) treated with intravitreal Avastin (bevacizumab) on an as-needed basis over 2 years finds that 43% of patients experienced a 3-line or more improvement in visual acuity (VA) and an average of 4.9 injections were administered over the 24-month follow-up period. In the...

The PrONTO Study has released results from the second year of follow-up of patients with wet age-related macular degeneration (AMD) that are treated with intravitreal Lucentis (ranibizumab) on an as-needed basis using optical coherence tomography (OCT) data that show as-needed treatment can achieve visual outcomes comparable to monthly Lucentis...